Juvenile Idiopathic Arthritis-associated Uveitis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis-associated Uveitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis [Phase 3]
Phase 3 study evaluating baricitinib in pediatric patients aged 2 to under 18 with active juvenile idiopathic arthritis-associated uveitis o…
-
CLINICAL_TRIALS trial_result · 2022-10-04Clinical Trial Update: Biologic Therapy in Pediatric JIA Uveitis [Phase 4]
Phase 4 trial update for a biologic therapy in pediatric JIA-associated uveitis.
-
CLINICAL_TRIALS trial_result · 2022-05-05Clinical Trial Update: Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
A completed clinical trial evaluating golimumab for juvenile idiopathic arthritis-associated uveitis that is failing adalimumab.
-
CLINICAL_TRIALS trial_result · 2018-11-27Clinical Trial Update: Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating tocilizumab for Juvenile Idiopathic Arthritis associated uveitis was terminated with results posted.